HTG Molecular Diagnostics (HTGM) Announces Earnings Results
HTG Molecular Diagnostics (NASDAQ:HTGM) announced its quarterly earnings results on Thursday. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.01, Morningstar.com reports. HTG Molecular Diagnostics had a negative return on equity of 132.67% and a negative net margin of 81.10%. The company had revenue of $4.71 million during the quarter, compared to the consensus estimate of $5.14 million. HTG Molecular Diagnostics updated its FY 2018 guidance to EPS.
Shares of HTGM stock traded down $0.49 during trading hours on Friday, hitting $3.65. 610,059 shares of the company’s stock were exchanged, compared to its average volume of 382,269. The company has a debt-to-equity ratio of 0.35, a current ratio of 9.50 and a quick ratio of 9.29. The company has a market cap of $118.23 million, a price-to-earnings ratio of -2.04 and a beta of 2.03. HTG Molecular Diagnostics has a fifty-two week low of $1.71 and a fifty-two week high of $5.83.
Hedge funds have recently made changes to their positions in the company. Spark Investment Management LLC acquired a new position in shares of HTG Molecular Diagnostics during the 2nd quarter worth approximately $663,000. FMR LLC increased its position in shares of HTG Molecular Diagnostics by 0.8% during the second quarter. FMR LLC now owns 3,488,045 shares of the medical research company’s stock worth $11,371,000 after purchasing an additional 27,700 shares in the last quarter. Stonepine Capital Management LLC purchased a new stake in shares of HTG Molecular Diagnostics during the second quarter worth approximately $5,506,000. Putnam Investments LLC increased its position in shares of HTG Molecular Diagnostics by 31.4% during the second quarter. Putnam Investments LLC now owns 1,387,883 shares of the medical research company’s stock worth $4,524,000 after purchasing an additional 331,690 shares in the last quarter. Finally, Granahan Investment Management Inc. MA increased its position in shares of HTG Molecular Diagnostics by 14.1% during the second quarter. Granahan Investment Management Inc. MA now owns 915,449 shares of the medical research company’s stock worth $2,984,000 after purchasing an additional 112,928 shares in the last quarter. 50.55% of the stock is owned by institutional investors and hedge funds.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
Featured Article: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.